Posts Tagged: "Parkinson’s Disease"

Successful Phase 1 Trial for Parkinson’s Vaccine

The study looked at groups of patients receiving various levels of the PD01A vaccine and evaluated them over a 12-month period. Patients receiving the vaccine were given PD01A subcutaneously in four vaccinations, either in doses of 15 micrograms or 75 micrograms… Of those who were immunized, 15 patients out of every 24 saw an increase in alpha-synuclein-specific antibodies. Interestingly, the antibody response was greater in the group of patients receiving the lower 15 microgram dose as compared to the group receiving the 75 micrograms of PD01A per vaccination. Also important was the fact that the vaccination was tolerated at the dosage levels administered and that there were no signs of a negative autoimmune response…

Steve Brachmann

August 7, 2014

Pharma & Biotech Update: News for October 2013

Mouse Model of Parkinson’s Disease Shows Improved Brain Function — DARPA Awards $25 Million To Develop Messenger RNA Therapeutics™ — Actavis Files ANDA for Generic Suboxone® Sublingual Film — AzaSite® Patents Upheld in Patent Infringement Lawsuit Against Sandoz — Surgeons Successfully Remove “Inoperable” Metastatic Breast Cancer — Actavis Files ANDA on Acanya® Gel, Gets Sued by Dow, Valeant — NYSE Inquires About Unusual Market Activity for Ampio Pharmaceuticals — Cannabis Biotech Hires Patent Attorney to Protect Medical Marijuana Innovation — Merck’s Hepatitis C Drug Gets Breakthrough Therapy Designation — Therapeutic Vaccine for Hepatitis C Enters Phase I — Urine Test for Cancer Monitoring — Popular Prenatal Vitamin Patent Upheld in District Court — Clinical Trials on Brain Technology to Assist ALS Patients — Teva Gets Favorable Ruling on COPAXONE in the Netherlands — BVGH Recruits Dr. Linda Venczel as New Program Director — Actavis’s settles with FTC over $8.5 Billion acquisition of Warner Chilcott

Gene Quinn

October 28, 2013